These findings are of great relevance, since significant side effects have been reported in leukemia patients upon treatment with PON [45], and we may therefore need to decrease the concentration of such TKi in therapeutic protocols adopted for childhood malignancies, while maintaining their efficacy. The gene discussed is PON1; the disease is leukemia.